Stifel Nicolaus Cuts X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $4.00

X4 Pharmaceuticals (NASDAQ:XFOR) had its price objective cut by Stifel Nicolaus from $5.00 to $4.00 in a report issued on Thursday,Benzinga reports. They currently have a buy rating on the stock.

X4 Pharmaceuticals Trading Down 1.6 %

Shares of NASDAQ XFOR opened at $0.40 on Thursday. The stock has a market cap of $67.99 million, a price-to-earnings ratio of -4.48 and a beta of 0.39. The business has a 50 day simple moving average of $0.58 and a 200 day simple moving average of $0.75. X4 Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $1.60. The company has a debt-to-equity ratio of 0.79, a quick ratio of 6.04 and a current ratio of 6.07.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings results on Wednesday, August 14th. The company reported $0.01 EPS for the quarter. The firm had revenue of $3.43 million during the quarter. On average, research analysts predict that X4 Pharmaceuticals will post -0.65 earnings per share for the current fiscal year.

Insider Activity at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 230,645 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $126,854.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Paula Ragan sold 239,436 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.55, for a total value of $131,689.80. Following the sale, the chief executive officer now directly owns 1,057,713 shares of the company’s stock, valued at $581,742.15. The trade was a 18.46 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 580,800 shares of company stock valued at $321,447. 1.62% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. SG Americas Securities LLC acquired a new position in shares of X4 Pharmaceuticals during the third quarter worth approximately $37,000. Ensign Peak Advisors Inc raised its stake in shares of X4 Pharmaceuticals by 4.6% in the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after purchasing an additional 111,032 shares in the last quarter. Rhumbline Advisers raised its stake in shares of X4 Pharmaceuticals by 14.6% in the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after purchasing an additional 23,831 shares in the last quarter. K2 Principal Fund L.P. acquired a new position in shares of X4 Pharmaceuticals in the second quarter valued at $284,000. Finally, XTX Topco Ltd acquired a new position in shares of X4 Pharmaceuticals in the second quarter valued at $65,000. 72.03% of the stock is currently owned by institutional investors and hedge funds.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.